Results 61 to 70 of about 10,900 (261)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

BMC Infectious Diseases, 2017
Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres, X. Carbonell-Estrany   +6 more
doaj   +1 more source

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada

American Journal of Perinatology, 2021
Objective This study aimed to evaluate palivizumab (PVZ) use, trends in indications, and outcomes of respiratory illness hospitalizations (RIH) and respiratory syncytial virus hospitalizations (RSVH).
I. Mitchell, Abby Li, C. Bjornson, K. Lanctôt, B. Paes   +4 more
semanticscholar   +1 more source

Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort [PDF]

, 2015
BACKGROUND: Respiratory Syncytial Virus (RSV) is one of the main causes of respiratory infections during the first year of life. Very premature infants may contract more severe diseases and 'late preterm infants' may also be more susceptible to the ...
Adorni F, Agosti M, Arco A, Aurilia C, Barberi I, Barboni G, Bertino E, Boldrini A, Bonomi A, Bottau P, Braibanti S, Carlucci A, Corona MF, Corsello G, Corso G, Coscia A, Dall’Agnola A, De Curtis M, De Luca MG, Del Vecchio A, Di Fabio S, Di Santo S, Ellero S, Fabiano A, Fabris C, Faccia P, Faldella G, Fanos V, Gabriele B, Gargano G, Girardi E, La Forgia N, Ladetto L, Lanari M, Loprieno S, Macagno F, Magaldi R, Memo L, Molinari L, Musicco M, Natale F, Negri C, Ngalikpima CJ, Nicolini G, Nosari N, Orfeo L, Paolillo P, Parmigiani S, Piano F, Prinelli F, Puddu M, Rinaldi M, Romagnoli C, Sarnelli P, Scarcella A, Silvestri M, Spinelli M, Umbaldo A, Vandini S, Vuerich M, Zorzi G   +60 more
core   +1 more source

An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling

Journal of Biological Chemistry
Recently, we phenocopied interleukin (IL-)6 signaling using the dimerized single-chain variable fragment (scFv) derived from the respiratory syncytial virus IgG1-antibody palivizumab (PscFvLHFc) to activate a palivizumab antiidiotypic nanobody (AIPVHH ...
Christoph Wittich, Julia Ettich, Marcel Hertell, Biswadeep Roy, Haifeng C. Xu, D. Floss, Philipp A. Lang, Jürgen Scheller   +7 more
semanticscholar   +1 more source

Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease

Journal of Pediatric and Neonatal Individualized Medicine, 2015
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route.
Karel Allegaert, Maissa Rayyan, Veerle Cossey, Chris Van Geet   +3 more
doaj   +1 more source

PIN69 Cost Utility Analysis of 13-Valent Pneumococcal Conjugate Vaccine in Malaysia [PDF]

, 2011
Farrando Sicilia, Jordi; Lecea, Ignasi de; Fuente Fuente, Carlos; Ribas Seix, Anna; Masana Padrós, Judit; Delgado, José ...
Wu, D.B.C., Lee, K.K., Lee, V.W., Hong, L.W., Roberts, C.S.   +4 more
core   +1 more source

Trends in Hospitalisations Due to Respiratory Syncytial Virus in Swedish Children: A Nationwide Study 2010–2022

Acta Paediatrica, EarlyView.
ABSTRACT Aim Respiratory syncytial virus (RSV) infection is a leading cause of paediatric hospitalisations. This study describes annual RSV‐hospitalisation burden of disease, by gestational week of delivery, age and sex among children aged 0–17 years of age in Sweden, for the period 2010/11–2021/22.
Kristian Bolin, Karin Strandell, Andreas Palmborg, Sofie Gustafsson, Sven‐Arne Silfverdal   +4 more
wiley   +1 more source

The influence of respiratory syncytial virus immunoprophylaxis on allergic sensitisation in children with respiratory allergy

Journal of Microbiology, Immunology and Infection
Background: Respiratory syncytial virus (RSV) infection may induce asthma and allergic sensitisation. RSV immunoprophylaxis can reduce the severity of RSV infections. However, the effects of RSV immunoprophylaxis on allergic sensitisation remains unclear.
Li-Ching Fang, Jen-Yu Wang
doaj   +1 more source

Early respiratory viral infections in infants with cystic fibrosis [PDF]

, 2015
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
A Peshkin, C Castoriadis, C Hauke, C Lasch, C Mayes, C Mayes, CG Jung, CG Jung, DC Dennett, I Semetsky, I Semetsky, J Blackmore, J Campbell, J Campbell, J Cole, J Conroy, J Conroy, J Day, J Lecoq, J Parini, JC Conroy, JR Searle, JV Wertsch, K Johnstone, K Kristjansson, LA Russell-Chapin, M Currie, M Harding, M Lynch, M Merleau-Ponty, R Leitch, R Leitch, R Leitch, R Segal, RH Hopcke, S Rowland, S Walsh, T Barone, V John-Steiner, V Villate, W James, W Sorrell   +41 more
core   +1 more source

The Effectiveness of the Palivizumab Programme in Reducing the Risk of Paediatric Asthma: A Population‐Based Study in Ontario, Canada

Paediatric and Perinatal Epidemiology, EarlyView.
ABSTRACT Background Palivizumab was introduced in Canada in 1998 as a publicly funded programme to reduce respiratory syncytial virus (RSV) disease in high‐risk children. Severe early‐life RSV infections are associated with increased asthma risk. Thus, palivizumab may also indirectly reduce paediatric asthma.
Kimberley A. Foley, Sarah A. Buchan, Dayre McNally, Michelle Dimitris, Sarah Swayze, Jeffrey C. Kwong, Steven Hawken, Sonia Saxena, Dougal Hargreaves, Tiffany Fitzpatrick   +9 more
wiley   +1 more source